NEW YORK (GenomeWeb) – Investment bank Piper Jaffray on Thursday initiated coverage of Veracyte with an overweight rating on the firm's stock and a $21 price target.
Registering provides access to this and other free content.
Already have an account?Login Now.
Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.
The Kansas City Star examines issues surrounding newborn genome sequencing.
Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.
In Science this week: the Human Silencing Hub protein complex, and more.